Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 18, 2026

The Vita Coco Company Reports Fourth Quarter and Full Year 2025 Financial Results

View original at globenewswire.com
The Vita Coco Company Reports Fourth Quarter and Full Year 2025 Financial Results Full Year Net Sales were $610 million, up 18%, driven by strong Vita Coco Coconut Water growth of 26% Full Year Net Income Increased $15 million to $71 million and Non-GAAP Adjusted EBITDA1 Increased $14 million to $98 million For Fiscal…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 2026 guidance is based on continued brand growth in major markets and improved private label trends based on expected new and regained business.

    80% confidence
  • Stable cost outlook is expected to enable the company to grow adjusted EBITDA in 2026 ahead of net sales growth rate.

    80% confidence
  • Full year shipment performance benefited from strong demand for Vita Coco Coconut Water and great execution from teams, producing double digit adjusted EBITDA growth despite significant tariff costs.

    80% confidence
  • Growth is being driven by investments as the category leader, resulting in increased household penetration and new consumption occasions.

    80% confidence
  • GAAP Net income 2026 outlook is not provided due to the inherent difficulty in quantifying certain amounts including unpredictability in foreign currency rate movements and future charges or reversals outside normal course of business.

    80% confidence
  • The coconut water category continues to be one of the fastest growing beverage categories and Vita Coco Coconut Water retail sales are growing at healthy rates in the United States and core international markets.

    80% confidence
  • Uncertainty and instability of the current operating environment, geopolitical landscape, and global economies, including changes in tariff rates, could affect the 2026 outlook.

    80% confidence
  • Vita Coco is well positioned to continue to drive growth based on category momentum, the strength of the Vita Coco brand and the performance of its supply chain.

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com